PATENT CLAIM ANALYSIS

Application Number: 16255690
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-08
Patent Classification: ["424", "139100"]

Abstract:
Provided are IFN-y-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.

Claim (Index 6):
The IRTCA antibody or antigen-binding fragment of  claim 1 , wherein the antibody or antigen-binding fragment binds to an epitope within the extracellular domain of human AITR polypeptide.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.41818
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15863526', '15507012', '14194797', '15495048', '14076214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7633163106736849
- 35 USC 102 Novelty (BERT): 0.5612053996354031
- Combined Prediction Score: 0.7431052195698566
- Mean Citation Score: 398.371636
- Max Citation Score: 428.79395
- Similarity Product: 347.22994120746847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test